NPS Estimates Gattex Initial Market At $150 Million To $250 Million
Company is seeking a pre-NDA meeting with FDA to discuss mixed top-line results from a Phase III study of the agent in short bowel syndrome.
Company is seeking a pre-NDA meeting with FDA to discuss mixed top-line results from a Phase III study of the agent in short bowel syndrome.